IL2 and ovarian cancer: Geller et al. (ClinicalTrials.gov identifier: NCT01105650) treated 14 ovarian cancer patients with haploidentical IL-2-activated NK cells followed by subcutaneous IL-2 infusions three times weekly for 14 days, detecting NK cell expansion in their peripheral blood [193].